Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday. Other equities research analysts also recently issued research reports about the company. Bank of America dropped their target price on Ascendis Pharma A/S from $132.00 […]